MLICM
FBRX icon

Metropolitan Life Insurance Company (MetLife)’s Forte Biosciences FBRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-140
Closed -$118K – 2845
2021
Q2 		$118K Buy
+140
New +$126K ﹤0.01% 2510

Other funds holding FBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s FBRX Position: Q3 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 140 shares — an estimated $118K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FBRX in Q2 2021 and held it in 1 quarter. The position peaked at $118K in Q2 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 140 Forte Biosciences shares in Q3 2021, an estimated $118K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Forte Biosciences in Q2 2021 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Forte Biosciences position peaked at $118K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2021, filed 15 Nov 2021.